Kanagarajan N, Nam J H, Noah Z Al, Murthy S
Drexel University College of Medicine, Office of Research Compliance, Philadelphia, PA 19102, USA.
Inflamm Res. 2008 Jan;57(1):34-8. doi: 10.1007/s00011-007-6177-4.
We evaluated the disease modifying effect of simvastatin and atorvastatin in Dextran Sulfate Sodium (DSS) model of colitis.
Thirty, 8-week old female Swiss-Webster mice were separated into 5 groups (n = 6/group). Colitis was induced by feeding 4 % DSS solution for 7 days. Following discontinuation of DSS, over the next 7 days, the groups orally received simvastatin (20 mg/kg/day), atorvastatin (60 mg/kg/day), vehicle only (0.75 % methylcellulose), subcutaneous 30 mug injections of anti-TNFalpha monoclonal antibody or intraperitoneal anti-mouse apolipoprotein A-I antibody respectively. Disease activity Index (DAI) was determined daily by a blinded investigator.
The mean reduction in DAI scores from day 7 to day 14 for anti-TNFalpha group, simvastatin and atorvastatin group were 74 %, 76 % and 64 %, respectively as compared to 41 % reduction in vehicle and anti-apolipoprotein A-I antibody-treated groups.
This finding suggests that statins may have the ability to modify the disease activity in the DSS model of colitis and the disease modifying effect is comparable to anti-mouse TNFalpha treatment in this model.
我们评估了辛伐他汀和阿托伐他汀在葡聚糖硫酸钠（DSS）诱导的结肠炎模型中的疾病改善作用。
将30只8周龄雌性瑞士韦伯斯特小鼠分为5组（每组n = 6）。通过喂食4% DSS溶液7天诱导结肠炎。停止喂食DSS后，在接下来的7天里，各实验组分别口服辛伐他汀（20毫克/千克/天）、阿托伐他汀（60毫克/千克/天）、仅服用赋形剂（0.75%甲基纤维素）、皮下注射30微克抗TNFα单克隆抗体或腹腔注射抗小鼠载脂蛋白A-I抗体。由一位不知情的研究者每天测定疾病活动指数（DAI）。
与赋形剂组和抗载脂蛋白A-I抗体治疗组41%的降低率相比，抗TNFα组、辛伐他汀组和阿托伐他汀组从第7天到第14天DAI评分的平均降低率分别为74%、76%和64%。
这一发现表明他汀类药物可能具有改善DSS诱导的结肠炎模型疾病活动的能力，且在该模型中其疾病改善作用与抗小鼠TNFα治疗相当。
